The content on this site is intended for healthcare professionals only
Dr Plesner presents, at a press conference at ASH 2015, updated results of a phase I/II study (GEN503) looking at daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
Read the news story and watch the video interview for more information.
Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma
Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma
New classification for identifying HR myeloma based on cytogenetic abnormalities
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing 1st line TKI Wisely in patients with CML
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
